Existing Partners
';
…committed to finding truly next-generation antibody technology. Adimab was spot on. —GlaxoSmithKline
…we engaged in a rigorous selection process and Adimab was the clear winner. —Biogen
…we are particularly impressed with the ability to optimize antibodies with this broad engineering tool. —Novo Nordisk
Adimab's technology does what no other technology can do. —Arsanis Biosciences
…one of the best, if not the best, platform out there… —GlaxoSmithKline
…a comprehensive solution for our antibody discovery needs. —Novo Nordisk
…just a fantastic partner! —Arsanis Biosciences
This deal is fantastic for GSK. —GlaxoSmithKline
From target to IND in less than 2 years. —Merrimack
We can use this approach for anything in the antibody space. —GlaxoSmithKline
We are very impressed with Adimab’s technology and science - they are a great partner. —Biogen
...Adimab's reputation as the leading protein engineering company in the industry is well deserved. —Innovent
The quality of Adimab's platform has consistently generated leads that are superior... —iTeos
The versatility and quality of the Adimab platform have been instrumental in supporting our CAR T cell therapies... —Kite Pharma
…committed to finding truly next-generation antibody technology. Adimab was spot on. —GlaxoSmithKline
…we engaged in a rigorous selection process and Adimab was the clear winner. —Biogen
…we are particularly impressed with the ability to optimize antibodies with this broad engineering tool. —Novo Nordisk
Adimab's technology does what no other technology can do. —Arsanis Biosciences
…one of the best, if not the best, platform out there… —GlaxoSmithKline
…a comprehensive solution for our antibody discovery needs. —Novo Nordisk
…just a fantastic partner! —Arsanis Biosciences
This deal is fantastic for GSK. —GlaxoSmithKline
From target to IND in less than 2 years. —Merrimack
We can use this approach for anything in the antibody space. —GlaxoSmithKline
We are very impressed with Adimab’s technology and science - they are a great partner. —Biogen
...Adimab's reputation as the leading protein engineering company in the industry is well deserved. —Innovent
The quality of Adimab's platform has consistently generated leads that are superior... —iTeos
The versatility and quality of the Adimab platform have been instrumental in supporting our CAR T cell therapies... —Kite Pharma
Platform Transfer
MerckAdimab has licensed and transferred the Adimab Platform to Merck and enabled Merck researchers to utilize the Adimab technology for the discovery and optimization of all antibody formats, including bispecific antibodies. Merck is the fourth pharmaceutical company to internalize the Adimab platform. Merck has received a custom human antibody library that is unique and exclusive to Merck and has a license to the Adimab Platform for use in all therapeutic areas. In addition, Merck has secured an option to receive continued improvements to the Adimab Platform, including access to new antibody libraries. Adimab has received an undisclosed upfront signing fee, plus future payments upon achievement of specified preclinical and clinical milestones, as well as royalties and additional future payments upon achievement of specified commercial milestones on therapeutic products. The platform transfer with Merck is an expansion from an initial relationship.
Novo NordiskAdimab has licensed and transferred the Adimab Platform to Novo Nordisk and enabled Novo Nordisk researchers to utilize the Adimab technology for the discovery and optimization of all antibody formats, including bispecific antibodies. Novo Nordisk is the third pharmaceutical company to internalize the Adimab platform. Novo Nordisk has received a custom human antibody library that is unique and exclusive to Novo Nordisk and has a license to the Adimab Platform for use in Novo Nordisk's targeted therapeutic areas. In addition, Novo Nordisk may access improvements to the platform during the term of the collaboration. Adimab has received an undisclosed upfront signing fee, plus future payments upon achievement of specified preclinical and clinical milestones, as well as royalties and additional future payments upon achievement of specified commercial milestones on therapeutic products. The platform transfer with Novo Nordisk is an expansion from an initial relationship.
BiogenAdimab has licensed and transferred the Adimab Platform to Biogen and enabled Biogen researchers to utilize the Adimab technology for the discovery and optimization of all antibody formats, including bispecific antibodies. Biogen is the second pharmaceutical company to internalize the Adimab platform. Biogen has received a custom human antibody library that is unique and exclusive to Biogen and has a license to the Adimab Platform for use in Biogen's targeted therapeutic areas. In addition, Biogen has secured an option to receive continued improvements to the Adimab Platform, including access to new antibody libraries. Adimab has received an undisclosed upfront signing fee, plus future payments upon achievement of specified preclinical and clinical milestones, as well as royalties and additional future payments upon achievement of specified commercial milestones on therapeutic products. The platform transfer with Biogen is an expansion from an initial relationship.
GlaxoSmithKlineAdimab has licensed and transferred the Adimab Platform to GSK and enabled GSK researchers to utilize the Adimab technology for the discovery and optimization of all antibody formats, including bispecific antibodies. GSK is the first pharmaceutical company to internalize the Adimab platform. GSK has received a custom human antibody library that is unique and exclusive to GSK and has a license to the Adimab Platform for use in all therapeutic areas. In addition, GSK has secured an option to receive continued improvements to the Adimab Platform, including access to new antibody libraries. Adimab has received an undisclosed upfront signing fee, plus future payments upon achievement of specified preclinical and clinical milestones, as well as royalties and additional future payments upon achievement of specified commercial milestones on therapeutic products.
Partners
AcceleronAdimab and Acceleron have initiated a research program whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies for Acceleron. The agreement grants Acceleron the right to develop and commercialize antibodies generated during the collaboration for potential use as therapeutic products. Acceleron will fund the research at Adimab and have the option to exclusively license antibodies generated during the collaboration. In addition, Adimab is eligible to receive license fees, clinical milestones and royalties on therapeutic product sales.
AlectorAdimab and Alector have entered into a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies against neurodegenerative-related targets selected by Alector. On a target basis, the agreement grants Alector the right to research antibodies generated during the collaboration for potential use as therapeutic products. Under the terms of the agreement, Adimab will receive undisclosed upfront payments. In addition, Alector will have the option to exclusively license antibodies generated during the collaboration. If Alector exercises its option for a particular target, Adimab would receive undisclosed downstream payments.
ArsanisAdimab and Arsanis have entered into a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies against multiple targets in the area of infectious disease. For each target, the agreement grants Arsanis the right to research antibodies generated during the collaboration for potential use as therapeutic products. Under the terms of the agreement, Adimab will receive undisclosed upfront payments. In addition, for each target, Arsanis will have the option to exclusively license antibodies generated during the collaboration. If Arsanis exercises its option for a particular target, Adimab would receive undisclosed downstream payments.
CelgeneAdimab and Celgene have entered into a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies against multiple targets. For each target, the agreement grants Celgene the right to research antibodies generated during the collaboration for potential use as therapeutic products. Under the terms of the Agreement, Adimab will receive an undisclosed upfront payment. In addition, for each target, Celgene will have the option to exclusively license antibodies generated during the collaboration. If Celgene exercises its option for a particular target, Adimab would receive license fees, clinical milestones and royalties on therapeutic product sales.
Eli LillyAdimab expands collaboration with Lilly. The latest agreement provides Lilly access to Adimab’s technology to discover and optimize multiple bispecific antibodies targeting molecular antigens identified by Lilly. Under the terms of the agreement, Adimab will receive upfront payments and is eligible to receive preclinical and clinical development milestone payments as well as royalties on product sales.
Five PrimeAdimab and Five Prime have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against one or more targets selected by Five Prime. The agreement gives Five Prime the option to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments and pre-clinical milestones. In addition, Adimab is eligible to receive clinical development milestones and royalties on product sales.
FortressAdimab and Fortress Biotech have initiated a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies and bispecifics against multiple targets selected by Fortress. The agreement grants Fortress the right to develop and commercialize antibodies and bispecifics generated during the collaboration for potential use as therapeutic products. Fortress will fund the research at Adimab and have the option to exclusively license antibodies and bispecifics generated during the collaboration. In addition, Adimab is eligible to receive license fees, clinical milestones and royalties on therapeutic product sales.
GenentechAdimab and Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) have initiated a research program whereby Adimab will use its proprietary yeast-based antibody discovery platform to identify fully human antibodies against two targets selected by Genentech. Under the terms of the agreement, Genentech has rights to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments, preclinical milestones and licensing fees. In addition, Adimab is eligible to receive clinical development milestones and royalties on therapeutic and diagnostic product sales.
GileadAdimab and Gilead have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against up to two targets selected by Gilead. The agreement gives Gilead the option to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments and preclinical milestones. In addition, Adimab is eligible to receive clinical development milestones and royalties on product sales.
Human Genome SciencesAdimab and Human Genome Sciences, of Rockville MD, have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against one target selected by Human Genome Sciences. The agreement gives Human Genome Sciences the option to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments and preclinical milestones. In addition, Adimab is eligible to receive clinical development milestones and royalties on product sales.
InnoventAdimab and Innovent have entered into a collaboration to generate therapeutic antibodies for a target selected by Innovent. Under the terms of the agreement, the parties will jointly coordinate the development, manufacture and commercialization of the therapeutic antibody. Innovent will compensate Adimab for the discovery and optimization of the therapeutic leads. Innovent will initially lead the development efforts, including cell line development, formulation, manufacturing and clinical trials. Adimab is required to reimburse Innovent for specific development costs. Innovent will retain rights for commercialization in China, with royalties owed to Adimab on product sales. Adimab will retain rights for commercialization in the US, Europe and Japan, with royalties owed to Innovent on product sales.
JounceAdimab and Jounce have entered into a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies against any target selected by Jounce. On a target basis, the agreement grants Jounce the right to research antibodies generated during the collaboration for potential use as therapeutic products. Under the terms of the agreement, Adimab will receive undisclosed upfront payments. In addition, Jounce will have the option to exclusively license antibodies generated during the collaboration. If Jounce exercises its option for a particular target, Adimab would receive undisclosed downstream payments.
KiteKite and Adimab have entered into a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies against selected targets. For each target, the agreement grants Kite the right to research antibodies generated during the collaboration for potential use in therapeutic CAR-T products. Kite will also have the option to exclusively license antibodies for development and commercialization as therapeutic CAR products. Adimab will receive an undisclosed upfront payment, research fees and technical milestones, as well as license fees, certain additional milestones and royalties on any therapeutic CAR product sales that are optioned under the agreement.
Kyowa Hakko KirinAdimab and KHK have entered into a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies against two targets selected by KHK. For each target, the agreement grants KHK the right to research antibodies generated from the collaboration for potential use as therapeutic products. Under the terms of the agreement, Adimab will receive various upfront fees including research fees and technical milestones. In addition, for each target, KHK will have the sole option to exclusively license antibodies from the collaboration, and if KHK were to exercise the option for a particular target, then Adimab would receive license fees, clinical milestones and royalties on therapeutic product sales for such target.
MD AndersonAdimab and MD Anderson Cancer Center have initiated a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies for MD Anderson against a selected target. Adimab grants MD Anderson the right to research antibodies generated during the collaboration for potential use in therapeutic products. MD Anderson will retain all commercial rights and have sole responsibility for the commercialization of the program. Adimab will receive undisclosed research fees to fund all discovery work, as well as downstream payments associated with license fees, milestones and royalties.
Memorial Sloan KetteringAdimab and Memorial Sloan Kettering (MSK) have initiated a collaboration whereby Adimab will use its proprietary discovery and optimization platform in combination with its proprietary rapid B cell isolation capabilities, to identify fully human antibodies for MSK against selected targets. For each target, Adimab grants MSK the right to research antibodies generated during the collaboration for potential use in therapeutic products. MSK will retain all commercial rights to each program. Adimab will receive undisclosed research fees to fund all discovery work, as well as downstream payments associated with license fees, milestones and royalties.
MerrimackAdimab and Merrimack Pharmaceuticals, have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against targets selected by Merrimack Pharmaceuticals. The agreement gives the Merrimack Pharmaceuticals rights to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments, preclinical milestones and licensing fees. In addition, Adimab is eligible to receive clinical development milestones, commercial milestones and royalties on therapeutic and diagnostic product sales.
NovartisAdimab and Novartis have entered into a collaboration whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against two targets selected by Novartis. The agreement grants Novartis the right to commercialize antibodies generated from the collaboration as therapeutic and diagnostic products. Under the terms of the agreements, Adimab will receive a combination of upfront payments, license fees, clinical milestones, and royalties on therapeutic and diagnostic product sales.
CascadianAdimab and Cascadian have initiated a research program whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies and bispecifics for Cascadian. The agreement grants Cascadian the right to develop and commercialize antibodies generated during the collaboration for potential use as therapeutic products. Cascadian will fund the research at Adimab and have the option to exclusively license antibodies and bispecifics generated during the collaboration. In addition, Adimab is eligible to receive license fees, clinical milestones and royalties on therapeutic product sales.
PfizerAdimab and Pfizer have entered into a collaboration whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against a Central Nervous System/Pain target selected by Pfizer. The agreement grants Pfizer the right to commercialize antibodies generated from the collaboration as therapeutic products. Under the terms of the agreements, Adimab will receive various upfront payments, preclinical milestones and licensing fees. In addition, Adimab is eligible to receive milestones and royalties on therapeutic and diagnostic product sales.
PotenzaAdimab and Potenza have initiated a research program whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies for Potenza. The agreement grants Potenza the right to develop and commercialize antibodies generated during the collaboration for potential use as therapeutic products. Potenza will fund the research at Adimab and have the option to exclusively license antibodies generated during the collaboration. In addition, Adimab is eligible to receive receive license fees, clinical milestones and royalties on therapeutic product sales.
RocheAdimab and Roche have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against a target selected by Roche. The agreement allows Roche the right to commercialize antibodies generated from the collaboration as therapeutic and diagnostic products. Under the terms of the agreements, Adimab will receive various upfront payments, preclinical milestones and licensing fees. In addition, Adimab is eligible to receive milestones and royalties on therapeutic and diagnostic product sales. Roche confirmed the successful delivery of several hundred IgGs within 8 weeks of starting an antibody discovery program with Adimab. The IgGs delivered met specific criteria as outlined in the contract.
SanofiAdimab and Sanofi have initiated a research program whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies and bispecifics against multiple targets for Sanofi. The agreement grants Sanofi the right to develop and commercialize antibodies and bispecifics generated during the collaboration for potential use as therapeutic products. Sanofi will fund the research at Adimab and have the option to exclusively license antibodies and bispecifics generated during the collaboration. In addition, Adimab is eligible to receive license fees, clinical milestones and royalties on therapeutic product sales.
Surface OncologyAdimab and Surface Oncology have initiated a research program whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies for Surface Oncology. The agreement grants Surface Oncology the right to develop and commercialize antibodies generated during the collaboration for potential use as therapeutic products. Surface Oncology will fund the research at Adimab and have the option to exclusively license antibodies generated during the collaboration. In addition, Adimab is eligible to receive license fees, clinical milestones and royalties on therapeutic product sales.
TizonaAdimab and Tizona Therapeutics have initiated a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies against multiple targets selected by Tizona. The agreement grants Tizona the right to develop and commercialize antibodies and bispecifics generated during the collaboration for potential use as therapeutic products. Tizona will fund the research at Adimab and have the option to exclusively license antibodies and bispecifics generated during the collaboration. In addition, Adimab is eligible to receive license fees, clinical milestones and royalties on therapeutic product sales.
TorqueAdimab and Torque have entered into a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies against selected targets. For each target, the agreement grants Torque the right to research antibodies generated during the collaboration for use in therapeutic nanoparticle products, with an option to exclusively license those antibodies for development and commercialization. Adimab will receive an undisclosed upfront payment, research fees and technical milestones, as well as license fees, certain additional milestones and royalties on any therapeutic nanoparticle product sales that are optioned under the agreement.
TuskAdimab and Tusk Therapeutics have initiated a research program whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies and bispecifics against multiple targets for Tusk. The agreement grants Tusk the right to develop and commercialize antibodies and bispecifics generated during the collaboration for potential use as therapeutic products. Tusk will fund the research at Adimab and have the option to exclusively license antibodies and bispecifics generated during the collaboration. In addition, Adimab is eligible to receive license fees, clinical milestones and royalties on therapeutic product sales.